Histone deacetylase enzymes as potential drug targets in cancer and parasitic diseases

37Citations
Citations of this article
51Readers
Mendeley users who have this article in their library.

Abstract

The elucidation of the mechanisms of transcriptional activation and repression in eukaryotic cells has shed light on the important role of acetylation-deacetylation of histones mediated by histone acetyltransferases (HATs) and histone deacetylases (HDACs), respectively. Another group belonging to the large family of sirtuins (silent information regulators (SIRs)) has an (nicotinamide adenine dinucleotide) NAD+-dependent HDAC activity. Several inhibitors of HDACs (HDIs) have been shown to exert antitumor effects. Interestingly, some of the HDIs exerted a broad spectrum of antiprotozoal activity. The purpose of this review is to analyze some of the current data related to the deacetylase enzymes as a possible target for drug development in cancer and parasitic diseases with special reference to protozoan infections. Given the structural differences among members of this family of enzymes, development of specific inhibitors will not only allow selective therapeutic intervention, but may also provide a powerful tool for functional study of these enzymes. Copyright © 2006 M. Ouaissi and A. Ouaissi.

Cite

CITATION STYLE

APA

Ouaissi, M., & Ouaissi, A. (2006). Histone deacetylase enzymes as potential drug targets in cancer and parasitic diseases. Journal of Biomedicine and Biotechnology. https://doi.org/10.1155/JBB/2006/13474

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free